Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Unjha Formulations's share price for the quarter that ended in Mar. 2026 was ₹20.29. Unjha Formulations's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 4.5 Mil. Therefore, Unjha Formulations's market cap for the quarter that ended in Mar. 2026 was ₹90.9 Mil.
Unjha Formulations's quarterly market cap
declined
from Sep. 2025 (₹114.0 Mil) to Dec. 2025 (₹112.0 Mil) and
declined
from Dec. 2025 (₹112.0 Mil) to Mar. 2026 (₹90.9 Mil).
Unjha Formulations's annual market cap
increased
from Mar. 2024 (₹84.7 Mil) to Mar. 2025 (₹97.8 Mil) but then
declined
from Mar. 2025 (₹97.8 Mil) to Mar. 2026 (₹90.9 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Unjha Formulations's Enterprise Value for Today is ₹91.0 Mil.
Unjha Formulations (BOM:531762) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Unjha Formulations Market Cap Related Terms
Unjha Formulations Market Cap Historical Data
* Premium members only.
The historical data trend for Unjha Formulations's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Unjha Formulations's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unjha Formulations Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unjha Formulations's Market Cap distribution charts can be found below:
* The bar in red indicates where Unjha Formulations's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Unjha Formulations's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unjha Formulations (BOM:531762) has a Market Cap of ₹107.0 Mil as of Jul. 23, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Unjha Formulations and its competitors. According to the industry distribution chart, Unjha Formulations ranks #990 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 96.8%.
Is Unjha Formulations' Market Cap too high?
Unjha Formulations' current Market Cap is ₹107.0 Mil. Based on the distribution chart, Unjha Formulations ranks #990 out of 1023 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Unjha Formulations has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Unjha Formulations' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Unjha Formulations ranks #990 out of 1023 companies for Market Cap. This places Unjha Formulations in the lower half of its industry. The industry median Market Cap is 211.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 211.56, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Unjha Formulations and its competitors. For the Drug Manufacturers industry, the median Market Cap is 211.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unjha Formulations's current Market Cap is ₹107.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unjha Formulations stock overvalued right now?
Based on GuruFocus' analysis, Unjha Formulations (BOM:531762) is currently considered Fairly Valued. The stock's GF Value™ is ₹23.14, compared to a current price of ₹23.89 — trading 3.2% above its estimated fair value. The current Market Cap is ₹107.0 Mil. Unjha Formulations' overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Unjha Formulations (BOM:531762), the current Market Cap is ₹107.0 Mil as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unjha Formulations (BOM:531762) Overvalued in 2026?
Based on GuruFocus' analysis, Unjha Formulations stock appears to be overvalued.
The current stock price of ₹23.89 is trading 3.2% above its estimated GF Value™ of ₹23.14.
GuruFocus considers Unjha Formulations to be Fairly Valued.
Key valuation signals for BOM:531762:
Market Cap: ₹107.0 Mil
GF Value™: ₹23.14 vs. price of ₹23.89 (3.2% above fair value)
No single metric tells the full story. See the BOM:531762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unjha Formulations Ltd is an India-based manufacturer and exporter of Ayurvedic products. The company products include Isabgol powder under the Fibron and Fibron SF name, and Sat-Isabgol and Isabgol Husk. It also offers human and veterinary medicines.
72GF Score
Get the complete analysis for BOM:531762
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531762 has been successfully added to your 
